QGEN QIAGEN N.V.

QIAGEN N.V. to release results for Q2 2024 and hold webcast

QIAGEN N.V. to release results for Q2 2024 and hold webcast

Venlo, The Netherlands, July 02, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the second quarter 2024.

Press release date / time: Wednesday, July 31, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.

Conference call date / time: Thursday, August 1, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time.

Three options for joining the conference call

Register for call back connection - Click here:

Service is available 15 minutes before the call starts

Dial-in by phone

U.S.:

UK: +44 (0)330 165 3655

GER: +49 (0)69 6610 2492

Conference ID: 8081810

To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.

Access the audio webcast - Click here:

A conference call replay will be available by using the following link:

Contact:

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample

to Insight solutions that enable customers to gain valuable molecular insights from samples

containing the building blocks of life. Our sample technologies isolate and process DNA,

RNA and proteins from blood, tissue and other materials. Assay technologies make these

biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases

interpret data to report relevant, actionable insights. Automation solutions tie these together

in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000

customers around the world in the Life Sciences (academia, pharma R&D and industrial applications,

primarily forensic) and Molecular Diagnostics (human healthcare).

As of March 31, 2024, QIAGEN employed 6,000 people in over 35 locations worldwide.





Further information can be found at .

source: QIAGEN N.V.

category: Financial



John Gilardi
QIAGEN N.V. 
 11
 

Domenica Martorana
QIAGEN N.V. 
 44
 
EN
02/07/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on QIAGEN N.V.

 PRESS RELEASE

QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointest...

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, further strengthening its syndromic testing portfolio in the United States. This marks QIAGEN’s second FDA clearance of a QIAstat-Dx panel in 2025, and builds on the authorization of five panels for use on the QIAstat-Dx system within the last 10 months. QIAGEN has now received regulatory clearances for three mini panels for detection of respirato...

 PRESS RELEASE

QIAGEN takes legal action to defend QuantiFERON intellectual property ...

VENLO, The Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A. (EPA: BIM) for patent infringement, reinforcing its commitment to protecting the scientific advancements behind its proprietary QuantiFERON technology. The complaint, filed in the Local Division of the Court of First Instance of the Unified Patent Court (UPC) in Duesseldorf, Germany, concerns European Patent EP 2 276 883 B2. This patent, which is one of many held by QIAGEN protecting the QuantiFERON technology, covers importan...

 PRESS RELEASE

QIAGEN Strengthens Global Bioinformatics Leadership With New Data Cent...

VENLO, The Netherlands & REDWOOD CITY, Calif.--(BUSINESS WIRE)-- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the official opening of a new data center in Melbourne, Australia, designed to strengthen its global bioinformatics leadership position in this region of the world. This latest addition reflects QIAGEN’s ongoing commitment to enhance its bioinformatics data infrastructure, enabling initiatives to broaden the reach and use of bioinformatics products in the Australia/Asia-Pacific region – which encompasses Australia, New Zealand, New Guinea and surrounding islands...

Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
Baptiste Salaville ... (+4)
  • Baptiste Salaville
  • Bruno Cavalier
  • Charlotte Vaisse
  • Jerôme Bodin

ResearchPool Subscriptions

Get the most out of your insights

Get in touch